Navigation Links
Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
Date:12/8/2013

NEW ORLEANS, Dec. 8, 2013 /PRNewswire-USNewswire/ -- Several new, targeted therapies show promise to expand treatment options for chronic lymphocytic leukemia (CLL) and are more effective and better tolerated than standard chemotherapy, according to studies presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans.

CLL is a blood cancer that occurs when abnormal white blood cells called lymphocytes accumulate in the blood, bone marrow, and lymph nodes or other organs, causing these organs to enlarge. Approximately 15,000 Americans are diagnosed with CLL every year, and nearly 70 percent of those affected are 65 or older. For some patients with a slower progressing disease, many physicians employ "watch and wait" strategies to minimize unnecessary toxic treatments. However, patients with high-risk features or a more rapidly progressing disease require prompt treatment.

While the current standard chemotherapy-based treatment regimen for patients with CLL has been effective in improving outcomes for these patients, it remains highly toxic, prompting additional research to identify strategies to further reduce the treatment burden. Newer drugs that more precisely target pathways and proteins known to trigger CLL development, and leave normal cells unharmed, are proving to be more effective in promoting cancer cell death while safer for the patient. Four studies presented today reveal data on the performance of several new CLL therapies that demonstrate potent effects on key regulators of cancer cell behavior.

"These exciting developments in CLL therapy represent a shift toward treatments that hone in on specific regulators of cancer, ultimately providing a safer and more effective treatment regimen," said Jennifer R. Brown, MD, PhD, Director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute in
'/>"/>

SOURCE American Society of Hematology
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CMTC announces Physician Collaboration Platform ("PCP") Upgrade: A cloud-based telehealth solution for improved collaboration, access and performance
2. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
3. Data for Investigational Tiotropium Show Improved Lung Function and Sustained Bronchodilation in Patients with Moderate Asthma Severity
4. UHC to Launch New Specialty Pharmacy Program for Better Continuity of Patient Care, Improved Access to Specialty Pharmaceuticals
5. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
6. How Those with Diabetes Who Overindulge Can Chew Their Way to Improved Health
7. Large-Scale Kaiser Permanente Program Linked to Improved Blood Pressure Control
8. Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
9. Ultra Solutions Debuts New Website Featuring Improved Navigability and Design
10. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
11. Ranbaxy Announces Improved Business Standards and Quality Assurance Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive ... regulatory and marketplace changes. CI leaders who adjust will ... In a new Best Practices, LLC study CI ... actionable insights, including: - Use secondary research ... primary research - Internal staff who are ...
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... , ROCKVILLE, Md., Dec. 9 Novavax, ... 25, 2009, it closed its previously announced public offering of ... Novavax received net proceeds from the sale of the ... approximately $21 million, which will be used for preclinical studies ...
... , GAITHERSBURG, Md, Dec. 9 Lentigen Corporation, ... of lentiviral gene delivery technologies, announced today that it ... business innovation research (SBIR) grant for a program on ... using Lentivirus". In this program, Lentigen will collaborate ...
Cached Medicine Technology:NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2
(Date:9/1/2014)... Steven Reinberg ... News) -- In a head-to-head comparison, an experimental drug ... and hospitalizations in heart failure patients. According to ... of the marked benefit of the new drug, dubbed ... those getting the standard medication, enalapril (Vasotec), either died ...
(Date:9/1/2014)... An operating theatre or operating room is ... operations. An operating room comprises a myriad of specially-designed ... lights, imaging displays as well as integration systems for ... Research, a U.S.-based market research firm, the operating room ... by 2019. , According to this report, the ...
(Date:9/1/2014)... Barcelona, Spain Monday 1 September 2014: Daily fruit ... up to 40%, according to research presented at ESC ... The findings from the seven year follow-up study of ... found that the more fruit people ate, the more ... "CVD, including ischaemic heart disease (IHD) and stroke, is ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Bioinformatics ... organize and analyze biological and genetic data. A ... activity of developing software tools to generate and ... be confused with biological computation. While bioinformatics simply ... of biology can its related concepts, biological computation ...
(Date:9/1/2014)... 2014 Ontraport , one of ... was developed to automate the small intricacies of managing ... Shane Michaels, prompting an investigative review. , “As ... of managing all of the small details involved with ... reports Michaels. “That’s why Ontraport has become so popular ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2
... , , , ... part of Mayo Clinic and Microsoft Corp.,s shared vision to help ... made enhancements to Mayo Clinic Health Manager , ... manage their health. People with conditions such as hypertension and high ...
... Germany: For the first time researchers have shown that by ... possible to make pancreatic cancer cells sensitive to chemotherapy, opening ... treat the disease. Dr Davide Melisi told Europe,s ... Berlin today (Thursday 24 September) that resistance to chemotherapy was ...
... New Series ... iPod touch. , ... (Vocus) September 24, 2009 -- Modality, Inc. and Elsevier, Inc. today announced two Procedures Consult ... help physicians, medical residents and students prepare for, perform and test their knowledge of the ...
... ... leader in automatic door sensors, BEA, Inc. is delighted our products will be welcoming ... center in the world with Gold LEED® (Leadership in Energy and Environmental Design) certification. ... Pittsburgh, Pa. ...
... ... is featured in a presentation and free downloadable slides on the Diabetes Best Practices ... Somerville, ... illnesses should focus on self-care and give them the survival skills necessary to maintain ...
... AMSTERDAM, September 24 Amsterdam Molecular,Therapeutics (Euronext: AMT), a ... Jorn Aldag as its new Chief Executive Officer, starting,October ... in the life,sciences sector and more than twenty five ... President and CEO of Evotec AG, he was,instrumental in ...
Cached Medicine News:Health News:Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol 2Health News:Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol 3Health News:Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy 2Health News:Procedures Consult Internal Medicine Applications Now Available on App Store 2Health News:Procedures Consult Internal Medicine Applications Now Available on App Store 3Health News:BEA Opens the Doors to the World at G20 Summit 2Health News:BEA Opens the Doors to the World at G20 Summit 3Health News:New Presentation Highlights Importance of In-Hospital Hyperglycemia Management and Appropriate Discharge Planning for Diabetes Patients 2Health News:AMT Appoints New Chief Executive Officer 2Health News:AMT Appoints New Chief Executive Officer 3
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the measurement of vaginal pH as part of a self examination programme to help reduce the risk of pre-term birth...
Medicine Products: